AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA therapeutics across several disease areas.

Allogene Therapeutics is cutting back to stretch its cash runway into the second half of 2027, laying off 28% of its workforce and focusing its resources on getting two clinical programs to inflection points. The off-the-shelf CAR-T cell therapy specialist disclosed the changes alongside delays to two milestones.

Kyverna Therapeutics may consider it had an “exceptional start to the year,” but that didn’t immunize the cell therapy biotech from the wider industry trend of layoffs.

Acelyrin’s shareholders have decided to power ahead with a planned merger with immune-mediated disease specialist Alumis despite the best efforts of an activist investor to derail the deal.

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway.

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that has already been cut, according to a May 13 statement from the Joint Task Force to Combat Anti-Semitism.

The announcement follows a five-year, $50 billion commitment from the Swiss pharma to expand its U.S. footprints in R&D and production.

It's markup week in the House for the 'one big, beautiful bill.' Lawmakers are debating significant programmatic changes to Medicaid as advocacy groups push back on Republicans' plans.

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma division weathered the storm from the loss of exclusivity in the U.S. of blockbuster Xarelto in the first quarter.